E-Cadherin (CDH1) genetic variations may be involved in invasion and metastasis of various cancers by altering gene transcriptional activity of epithelial cells. However, published studies on the association of CDH1 gene polymorphisms and prostate cancer (PCA)risk remain contradictory, owing to differences in living habits and genetic backgrounds.To derive a more better and comprehensive conclusion, the present meta-analysis was performed.Electronic searches of several databases were conducted for all publications on the association between the CDH1 -160 C/A polymorphism and prostate cancer before Oct 2014. The odds ratio (OR) and its 95% confidence interval (CI) were used for statistical analysis.A total of 7 eligible studies including 1294 cases and 1782 controls were involved in this meta-analysis.Overall, meta-analysis indicated that the -160A allele carriers (AA, CA, AA+CA and A allele) had an increased risk of PCA compared with the homozygotes (CC). In the subgroup analyses by ethnicity, a positive association was found in Asians with A allele, AA, CA, AA+CA genotype and Caucasian descendants with AA genotype, dominant and recessive models. On the contrary, a decreased prostate cancer risk was found in Africans with heterozygous,dominant and allele models.Taken together,this meta-analysis showed that the CDH1 -160A allele might be a risk factor for prostate cancer in Asians and Caucasians. However, this result should be verified by additional population-based studies with large sample sizes.
Introduction
Prostate cancer is the most common cancer among men and the second leading cause of cancer death in men. 1 The mechanism of prostatic tumorigenesis is still not fully understood. Evidence from epidemiological and genetic studies provides more focus on the inherited susceptibility to cancer. It is likely that gene environment interactions are involved in tumorigenesis and development. 2 Among these genetic factors, the E-cadherin (CDH1) gene, consists of a large extracellular domain composed of smaller transmembrane and cytoplasmic domains and five repeat domains. 3 CDH1, located on chromosome 16q22.1, is one of the most important tumor suppressor genes encoding an adhesion glycoprotein. [4] [5] Several polymorphisms and somatic mutations have been identified in CDH1. 6 It also plays important roles in such aspects of establishment and maintenance of cell polarity and tissue architecture and intracellular adhesion. 7 Therefore, abnormal expression of CDH1 is often occurred in a number of human epithelial cancers. Aberrant CDH1 functions have been reported to be associated with malignant transformation of prostatic epithelium as well as metastasis and poor prognosis of PCA. [8] [9] A number of studies had investigated the roles of CDH1 gene polymorphisms in human prostate cancers risk, but the results were not consistent. Therefore, we performed a search of relevant literatures and carried out a meta-analysis to obtain a more accurate evaluation of the association between CDH1 genetic polymorphisms and prostate cancer.
Methods

Publication selection
Electronic databases (PubMed, Embase, the Cochrane Controlled Trials Register,the Science Citation Index,and the Chinese Biomedical Database) were searched independently by two authors for all publications regarding the association between the E-Cadherin polymorphism and prostate cancer before Oct 2014. The keywords were as follows: CDH1/ E-Cadherin/ polymorphism/ prostate cancer. A comprehensive search of reference lists of all review articles and original studies retrieved by this method was performed to identify additional reports.. The results were limited to papers with full-text and published in the English language.
Inclusion and exclusion criteria
Studies estimating the association between CDH1 genetic polymorphisms and prostate cancer risk had to mee all of the following criteria: 1) published in English 2) they were original epidemiological studies on the correlation between CDH1 genetic polymorphisms and prostate cancer susceptibility; 3) case-control studies; 4) sufficien information provided to estimate odds ratios (ORs) with 95% confidence intervals (CIs). However, duplicated studies, case-only studies, case reports, unpublished data letters, comments, and reviews must be excluded.
Data extraction
Two investigators independently extracted the data and reached a consensus on all the items according to the inclusion criteria listed above. For each study, the following characteristics were collected: author's first name, year of publication, country of origin, ethnicity, definition of cases, genotyping method, sources of control and case groups, total number of cases and controls, as well as number of cases and controls with AA,CA and CC genotypes.
Statistical methods
For the control group of each study, the observed genotype frequencies of the CDH1 polymorphism were assessed for Hardy-Weinberg equilibrium using the Pearson chi-squared test; P<0.05 was considered to be statistically significant.
Based on both fixed effects and random-effects models, a pooled odds ratio (OR) with 95% confidence interval (CI) was used to assess the strength of association between CDH1 -160 C/A polymorphisms and prostate cancer risk, depending on the heterogeneity of the analysis. The pooled ORs were also assessed for -160 C/A by homozygous (AA vs CC), heterozygous (CA vs CC),recessive (AA vs CC+ CA) and dominant models (AA +CA vs CC) as well as allele comparison (A vs.C).
Heterogeneity was evaluated using the Q test and I 2 score. If the result of the heterogeneity test was P>0.1, ORs were pooled according to the fixed-effects 
Results
Study Selection
The electronic search strategy identified 31 potentially relevant articles, which were evaluated further in detail, including their titles, abstracts, full text, or a combination of these.Twenty-four articles were excluded ( Figure 1 ). Nine studies were not focused on prostate cancer and seven were not focused on the CDH1 polymorphism. Six studies were laboratory studies, and one study was a systematic review. One study 10 was eliminated because it did not follow Hardy-Weinberg equilibrium, indicating that these groups might not represent the general population very well. Finally, seven studies 11-17 on CDH1 genotypes and prostate cancer risk including a total of 1294 prostate cancer cases and 1782 controls were identified. Table 1 showed the characteristics of the studies included in this meta-analysis.A total of seven publications met the inclusion criteria. [11] [12] [13] [14] [15] [16] [17] All of them are case-control studies. Almost all of the cases were histologically confirmed. The controls were mainly healthy populations except for some having benign prostatic hyperplasia. There were three studies of Asians, two studies of Caucasians, and two studies of Africans.Genotyping methods used in the studies included polymerase chain reaction(PCR)-restriction fragment length polymorphism (RFLP),TaqMan-assay, and dynamic allele-specific hybridization(DASH).The distribution of genotypes among the controls was consistent with the Hardy-Weinberg equilibrium (P>0.05) in all studies.
Study Characteristics
Quantitative data synthesis
The results for associations between -160C/A polymorphism and prostate cancer risk and for heterogeneity testing are shown in 
Tests of heterogeneity
Statistically significant heterogeneity was found between the trials using the Q statistic and I 2 score (A versus C, P=0.006, I 2 =67%; CA versus CC, P=0.003, I 2 =70%; the dominant model AA+CA versus CC, P=0.001, I 2 =73%). The random-effects model was employed in these studies. There was no significant heterogeneity between the following comparisons: AA versus CC (P=0.34, I 2 =12%) and recessive model AA versus CC+CA (P=0.62, I 2 =0%, Table 2 ), and the fixed-effects model was employed in these studies.
Sensitivity analysis
Sensitivity analysis was conducted to assess the stability of the results by sequential removal of each eligible study. The significance of the pooled ORs was not influenced by any single study, indicating that our results were statistically robust(data not shown).
Publication bias
Begg's test and Egger's test were used to assess for publication bias. Egger's weighted regression did not indicate publication bias (A versus C, P=0.855; AA versus CC, P=0.942; CA versus CC, P=0.832; dominant model AA + CA versus CC, P=0.686; recessive model AA versus CC + CA, P=0.629).This was confirmed by Begg's rank correlation (A versus C,P=1.000; AA versus CC, P=1.000; CA versus CC, P=0.443;dominant model AA + CA versus CC, P=0.443; recessive model AA versus CC + CA, P=1.000, Table 3 ).
Discussion
Many studies have attempted to reveal the genetic basis of prostate cancer.
Despite suggestive evidence of gene association, reports have been difficult to replicate, indicating that prostate cancer is more genetically heterogeneous than initially believed. The polymorphisms of CDH1 may play a critical role in the tumorigenesis, development and prognosis of sever kinds of cancer, such as urothelial cancer, colorectal cancer, gastric cancer, prostate cancer, breast cancer and esophageal cancer. [18] [19] [20] [21] [22] [23] Because PCA is one of the most common malignant diseases among men and a number of studies have reported a function of the CDH1 -160 C>A polymorphism in PCA risk with inconclusive results, we performed this meta-analysis to estimate the association specifically. At the same time, because the same polymorphism seemed to have different functions in cancer susceptibility among different ethnic populations and because the frequencies of single-nucleotide polymorphisms might be different among different ethnic groups, subgroup analyses on the basis of ethnicity were conducted.
We concluded that rs16260 A allele was obviously associated with increased cancer risk based on 1294 cases and 1782 controls in overall pooled results from 7 studies. A stratified analysis by cancer type indicated that rs16260 AA genotype increased risk of prostate cancer. Subsequently stratified analysis by country indicated borderline increased cancer risk was found in Asian and Caucasian population. In contrast, results appeared in African population revealed that -160C/A polymorphism was related with decreased risk of prostate cancer.This may be related with different genetic background and the environment exposure 24 or the different frequency of rs16260 A allele variant in this study. In addition, it is also possible that the observed ethnic differences may be due to chance because studies with small sample size may have insufficient statistical power to detect a slight effect or may have gene-rated a fluctuated risk estimate. 25 
